For the first time in pharmaceutical history, molecules designed almost entirely by artificial intelligence are surviving Phase 2 trials in real patients. From Insilico’s rentosertib to Isomorphic Labs’ multi-billion dollar…
Mitochondrial transplantation, once a fringe idea, is now being tested in human clinical trials for heart failure, stroke, and age-related cellular decline. A new wave of 2026 research shows that…
A Stanford University study of 44,498 people and 2,916 blood proteins has mapped the biological age of 11 organs and identified a startling finding: a biologically aged brain carries Alzheimer’s…
A landmark 2026 study in Nature Aging reveals that phosphoenolpyruvate (PEP), a glycolytic metabolite, acts as a natural brake on the cGAS-STING inflammatory pathway. As PEP levels decline with age,…
A landmark Science study reveals that genes control over 50 percent of lifespan variation. Meanwhile, the PROACT trial uses polygenic risk scores to find hidden heart disease, and whole genome…
A closer look at Yamanaka factors, partial reprogramming, David Sinclair, Altos Labs, and the widening gap between real age-reversal science and the hype surrounding it.
First-generation senolytics like dasatinib plus quercetin showed only subtle effects in human trials. A new generation of senolytic CAR-T cells borrows cancer immunotherapy and retrains it to hunt senescent cells….
A cluster of landmark studies is forcing scientists to ask a radical question: could the drugs that conquered obesity also slow the biological clock? The answer is more complicated, and…
A landmark 2021 Stanford study found that a diet rich in fermented foods increased gut microbiome diversity and lowered 19 inflammatory proteins, while a high fiber diet did not. Here…
Roughly one in five adults worldwide carries a genetic condition that roughly doubles their lifetime cardiovascular risk. Lipoprotein(a) is invisible to standard cholesterol panels, cannot be lowered by diet or…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.